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Abstract
Background: Hepatitis C virus (HCV) infection is a pandemic causing disease; more than 185 million people are
infected worldwide. An HCV antibody (Ab) prevalence of 6.0% was estimated in Central African countries. The study
aimed at providing HCV prevalence estimates among pregnant women in Rwanda.
Methods: HCV surveillance through antibody screening test among pregnant women attending antenatal clinics
was performed in 30 HIV sentinel surveillance sites in Rwanda.
Results: Among 12,903 pregnant women tested at antenatal clinics, 335 (2.6% [95% Confidence Interval 2.32–2.87])
tested positive for HCV Ab. The prevalence of HCV Ab in women aged 25–49 years was 2.8% compared to 2.4% in
women aged 15–24 years (aOR = 1.3; [1.05–1.59]); This proportion was 2.7% [2.37–2.94] in pregnant women in
engaged in non-salaried employment compared to 1.2% [0.24–2.14] in those engaged in salaried employment
(aOR = 3.2; [1.60–6.58]). The proportion of HCV Ab-positive co-infected with HIV was estimated at 3.9% (13 cases).
Women in urban residence were more likely to be associated with HCV-infection (OR = 1.3; 95%CI [1.0–1.6])
compared to those living in rural setting.
Conclusion: HCV is a public health problem in pregnant women in Rwanda. Few pregnant women were co-infected
with HCV and HIV. Living in urban setting was more likely to associate pregnant women with HCV infection.
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Background
The global prevalence of hepatitis C virus (HCV) infection
was estimated between 1.2 and 3.8% according to
World Health Organization (WHO) Global Burden
Disease (GBD), with more than 185 million people
infected worldwide [1–4]. The region with the highest
reported HCV prevalence in the world was found in
Central Asia (3.8%). In sub-Saharan Africa, the preva-
lence was 2.3% [1, 5].
A study conducted in specific sub-Saharan African
countries estimated a high prevalence of HCV (6.0%) in
central African countries. In North Africa, Egypt has the
highest HCV prevalence (17.5%) followed by Morocco
(7.7%) [6, 7].
In Rwanda, HCV seroprevalence studies have been
limited to HIV- infected persons only [8, 9]. A study
conducted among adults in one HIV clinic in the capital,
Kigali in 2010, showed that the prevalence of HCV anti-
body (anti-HCV) was 5.7% [8]. The second found a
sero-prevalence of 2.1% among HIV-infected persons in
Rwanda [9].
Sexual and maternal to child transmission and house-
hold exposure are not listed among major factors of
HCV transmission [2, 6]. The transmission of HCV
from mother to child is estimated at 4–8%, but the
transmission rate increases to 17–25% if the mother is
also HIV infected [10]. In sub-Saharan Africa the main
factor of HCV prevalence is blood transfusions and un-
sterile injections [6].
The prevalence of HCV infection among pregnant
women was estimated between 1 and 8% worldwide
[11]. In the Arabian Peninsula and North African
(Maghreb) region, HCV among pregnant women ranges
from 8.6% in Egypt to less than 1% in Libya [12]. In
Nigeria, a study conducted among pregnant women,
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found that the prevalence of HCV ranged between 1.4%
for women aged between 20 and 35 years old and
11.1% for women aged less than 20 years old [13]. In a
systematic review and meta-analysis study published in
2015, conducted in 21 sub-Saharan African countries,
found that the overall HCV prevalence among pregnant
women in antenatal clinic was 3% and was 2% in the
Central African region [14].
The burden of HCV infection in the general population
and among pregnant women is unknown in Rwanda. The
objective of the current study in Rwanda was to determine
the prevalence and factors associated with testing positive




In 2011, an HIV cross-sectional sero-surveillance activity
included HCV antibody testing among other tests per-
formed in pregnant women from June 2011 to December
2011. A signed informed consent was used.
Setting and sites
In Rwanda before 2005, only 24 sentinel sites partici-
pated in HIV surveillance. In order to be more represen-
tative, the number was increased to 30 sentinel sites in
2005, with 14 located in urban areas and 16 in rural
areas. Each province has at least two urban and two
rural sites. Inclusion criteria for sites were: at least 80
new women enrolled for ANC services per month,
geographically accessible, at least one midwife or a nurse
experienced in maternity or ANC, and one laboratory
technician. Hepatitis C screening was added in the 2011
survey.
Sentinel population
All pregnant women aged 15–49 years presenting for
the first time for their current pregnancy for antenatal
clinic and prevention of mother-to-child transmission
(ANC-PMTCT) services during the data collection
period and voluntarily agreeing to a venous blood draw
for HIV and syphilis testing routine testing, were en-
rolled in the survey. Personal socio-demographic charac-
teristics were collected using a surveillance form that
was complete through interview conducted by trained
data collectors who were also health center regular staff.
The option of linking personal data was used to return
hepatitis results to participants.
Women younger than 18 years were accompanied by
an adult guardian and signed assent form to allow the
participation in the survey. A sample size of 13,267 will
result in a relative 10% precision around a point estimate
(HIV prevalence) of 3% among pregnant women attend-
ing ANC at an alpha of 0.05 and power of 0.80.
Laboratory methods
Hepatitis C virus testing
All hepatitis C screening tests were performed at the
central level at the National Reference Laboratory (NRL)
in Kigali. Hepatitis C antibody (HCV Ab) using Abbott
ARCHITECT system included, Reagents, calibrator, con-
trol packs, Pre-Trigger Solution and Probe Conditioning
Solution for the assays for screening for prior exposure
to hepatitis C and/or current infection.
HIV testing
HIV testing was performed at the health facility on all
eligible and consenting pregnant women samples using
3 rapid test algorithm in order to provide without delay
HIV test result to participants for counseling and clinical
management for HIV-positive according to the national
testing guidelines.
For the survey quality assurance purpose, all positive
and 10% of the negative were sent to NRL for retesting
using ELISA-based HIV testing algorithm.
Data collection
Data collectors were selected among health facility staff.
At each health facility, focal persons, including the
Director and one laboratory technician, were selected
to carry out data collection. Five-day training was orga-
nized to familiarize staff with the protocol, laboratory
techniques related to the surveillance, and standard
operating procedures (SOPs). Participants were con-
secutively enrolled according to the inclusion criteria
until the determined sample size at the site was
reached. A structured sero-surveillance questionnaire
was administered to all eligible pregnant women at-
tending ANC/PMTCT service. Forms were kept in a se-
cure place at the sentinel sites and transported to the
Rwanda Biomedical Center (RBC) after every 2 weeks
during regular site supervision visits. Questionnaires
and laboratory results were double-entered using Epi
Info (CDC, Atlanta, GA) at RBC.
Data analysis
STATA software (StataCorp LP, 4905 Lakeway Drive,
College Station, TX, USA) was used for data analysis.
HCV prevalence, HCV-HIV co-infection proportions and
95% confidence limits were estimated separately by levels
of socio-demographic factors. Bivariate logistic regression
analysis was used to test for associations between screened
HCV infection and potential risk factors. The multivariate
analysis was performed to determine factors that were as-
sociated with HCV infection in the bivariate analysis at
the ≤0.1 significance level to develop the final multi-
variable model using a backward elimination method. All
variables were modeled as categorical variables to check
on potential interactions and associations. None of the
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tested interaction terms between age and marital status
and age and education was significant. The prevalence of
screened HCV, among pregnant women was estimated at
95% confidence intervals. The risk factors for HCV infec-
tion among pregnant women attending ANC services
were determined from covariates fitted in the multi-
variable logistic regression analysis: age, marital status,
education level, occupation, residence, parity and, HIV
infection.
Ethical considerations
In 2011, blood specimen and interview-based data
collection was only performed on volunteers eligible
participants who provided informed consent. The
survey was reviewed in accordance with CDC human
subjects review procedures and was determined to be a
non-research routine disease surveillance activity. The
survey was approved by the Rwandan National Ethics
Committee.
Results
Of, 13,292 pregnant women enrolled in the survey,
63.8% were 25 years old and above, 87.2% were married
or cohabitating and 88.6% were illiterate. By source of
income, 96.1% were not salaried. A proportion of 39.5%
of women were at their 2–3 parity, 30.7% were at their
first parity. Among all pregnant women, 12,903 (97.1%)
were screened for HCV Ab, 335 (2.6%) [95%CI: 2.3–2.9]
were identified HCV Ab-positive.
The prevalence of HCV-screened positive was 2.4%
[95% CI: 1.6–3.2] among single pregnant women, 2.7%
[95% CI: 2.3–2.9] among married pregnant women, and
3.9% [95% CI: 1.2–6.5] among separated, divorced or
widowed pregnant women. The prevalence of HCV-
screened positive was higher in pregnant women with
low education level (illiterate and primary education
level) compared to those with high education level
(secondary and university education level): 2.7% [95%
CI: 2.4–3.0] for illiterate pregnant women or pregnant
Table 1 Hepatitis C virus and HIV co-infection among pregnant women attending ante-natal clinics in Rwanda, 2011
Characteristics Total Hepatitis C prevalence HIV co-infection proportion among HCV Ab- positive
N n % [95% C.I] n % [95% C.I]
Age group
15–24 4,669 109 2.3 [1.91–2.77] 1 0.9 [-0.78–2.38]
25–49 yrs 8,160 226 2.8 [2.41–3.13] 12 5.3 [1.76–6.19]
Marital status
Single 1,438 35 2.4 [1.64–3.23] 1 2.9 [-1.94–5.78]
Married/Cohabiting 11,166 291 2.7 [2.32–2.92] 11 3.8 [1.30–4.94]
Divorced/Separated/Widow 207 8 3.9 [1.22–6.51] 1 12.5 [-5.47–15.47]
Education
Illiterate/Primary 11,319 305 2.7 [2.40–2.99] 12 3.9 [1.40–4.99]
Secondary/University 1,468 26 1.8 [1.96–2.45] 1 3.8 [-2.25–6.55]
Employment
Salaried(Salaried employee + Housemaids) 505 6 1.2 [0.24–2.14] 1 16.7 [-26.18–59.60]
Non-salaried 12,268 326 2.7 [2.37–2.94] 12 3.7 [1.27–4.49]
Residence
Rural 6,416 151 2.4 [1.98–2.73] 4 2.6 [0.77–6.76]
Urban 6,487 184 2.8 [2.43–3.25] 9 4.9 [1.17–4.75]
Number of Pregnancies
1 Pregnancya 3,886 100 2.6 [2.75–3.72] 0 0.0
2-3 pregnancies 4,944 130 2.6 [2.18–3.76] 8 6.2 [1.25–6.67]
4-5 pregnancies 2,384 61 2.6 [1.92–3.19] 4 6.6 [0.84–7.26]
> = 6 pregnancies 1,356 38 2.8 [1.92–3.68] 1 2.6 [-3.62–1.51]
HIV status
Negative 12,463 322 2.6 [2.36–2.86] - - -
Positive 429 13 3.0 [1.42–4.66] 13 100
Total 12,903 335 2.6 [2.32–2.87] 13 3.9 [1.40–4.66]
aIncluding the current one
Note: The denominator for co-infection is HCV Ab-positive
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women with primary education level vs. 1.8% [95%CI:
2.0–2.4 with secondary or university level]. Prevalence
of HCV-screened positive was higher among pregnant
women in unsalaried employment compared to preg-
nant women in salaried employment with 2.7% [95%CI:
2.4–3.0] and 1.2% [95%CI: 0.2–2.1] respectively
(Table 1)
HIV infection among HCV Ab positive was analyzed.
Out of 335 screened HCV Ab-positive, 13 women were
co-infected with HIV. The proportion of HIV infection
among HCV-infected women was estimated at 3.9%
[95% CI: 1.4–4.7]. This co-infection among HCV infected
women varied in the different socio-demographic charac-
teristics of pregnant women attending ANC (Table 1).
Education level, employment and residence were
considered in determining factors associated with
HCV infection (Table 2). In multivariate analysis,
there is evidence that HCV among pregnant women
was associated with urban residence with aOR = 1.3
[95% CI: 1.0–1.6].
Discussion
All attendees to ANC services participated in the study
and all consented for HCV testing. The overall preva-
lence of HCV Ab screened positive among pregnant
women in sentinel sites in Rwanda was estimated at
2.6%. Due to insufficient blood sample, 2.9% of partici-
pants were not tested for HCV. Pregnant women aged
between 25 and 49 years were more likely to be infected
with HCV than younger pregnant women (15–24 years
old). The proportion of HIV-positive among HCV Ab-
positive pregnant women in ANC sentinel surveillance
sites was (3.9%).
The HCV prevalence among pregnant women in senti-
nel sites in Rwanda was similar to the overall HCV
prevalence in sub-Sahara African countries (3.0%) and
the prevalence of HCV in Central African region (2.0%)
[13]. It was also similar to the prevalence using con-
firmed HCV-positive tests in Malawi (2.0%) [15], and
higher than the HCV prevalence among pregnant
women in Brazil, United Kingdom (London) and Nigeria
Table 2 Hepatitis C Virus infection associated factors among pregnant women attending ante-natal clinics in Rwanda, 2011
Bivariate Multivariable
cOR p-value [95% CI] aOR p-value [95% CI]
Age group
15–24 years
25–49 years 1.19 0.14 [0.95,1.50] -
Education
Illiterate/primary
Secondary/University 0.65 0.04 [0.43,0.98] 0.69 0.10 [0.45,1.07]
Marital status
Single
Married/cohabiting 1.07 0.70 [0.75,1.53] -
Divorced/Separated/Widow 1.61 0.23 [0.74,3.52] -
Employment
Salaried
Non-salaried 0.04 [1.00,5.12] 1.87 0.15 [0.80,4.40]
Residence
Rural
Urban 1.21 0.09 [0.97,1.51] 1.28 0.03 [1.02,1.60]
Pregnancies
1 Pregnancy
2-3 pregnancies 1.02 0.87 [0.79,1.33] -
4-5 Pregnancies 0.99 0.97 [0.72,1.37] -
> = 6 Pregnancies 1.09 0.65 [0.75,1.59] -
HIV status
Negative
Positive 1.18 0.57 [0.67,2.07] -
NB: If the bivariate p-value was >0.1 – variable was not included in multivariable analysis
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of 0.2, 0.8 and 1.5% respectively [12, 15]. In the African
region, the prevalence of HCV in the general population
widely varied by country, ranging from 0.1 to 17.5% [7].
The increase of HCV with age was observed in a study
conducted in Brazil among pregnant women in 2009
[16] and in all African regions [9]. A study of a global
epidemiology of hepatitis C virus infection found that
HCV prevalence increased with age with different HCV
prevalence peak in different ages in different regions [1].
The HCV and HIV co-infection proportion among preg-
nant women attending the ANC services in Rwanda was
3.9%.
The HCV and HIV co-infection was low among
HCV-positive pregnant women in Rwanda. The pro-
portion of the co-infection was lower compared to
published studies in sub-Sahara countries (16.0%) and
in Central African region (6.0%). A Brazilian study
published in 2009 reported 7.0% of HCV-positive
pregnant women were co-infected with HIV-1 [15]. In
European countries, among HIV-positive enrolled
pregnant women this co-infection was very high
(12.3%) [17]. In 2010, a meta-analysis [15] focusing on
HIV and HCV co-infection using published studies in
consecutive years from several sub-Saharan African
countries for adult people published the following re-
sults: In 2006 HCV and HIV co-infection was 4.8% in
Burkina Faso and in 2007, it was 8.6% in Cameroon.
In 2008 HCV and HIV co-infection in Ethiopia was
1.8%; 1.8% in Kenya, 1.1% in Malawi, 15.7% in
Mozambique, 8.0% in Senegal, 13.4% in South Africa
and 18.1% in Tanzania. In another study, it was re-
ported that HCV and HIV co-infection in Nigeria was
3.8% in 2009 [14].
A significant difference in odds of having HCV was
observed among pregnant women in urban residence
compared to rural residence. That is, the HCV risk was
higher in the urban than the rural women. The assump-
tion behind this situation is the usual location of key
population in urban setting than in rural ones.
In our study, there was no evidence to suggest a sig-
nificant association between HIV and HCV infections.
Similar observations were made in a study conducted in
Kigali among adult HIV-positive persons [8].
The co-infection of HIV and HCV is associated with
high mortality due to liver diseases compared to
mono-infection [18]. Therefore, HIV is considered an
important risk factor for HCV in the general popula-
tion but has not been widely investigated. Most pub-
lished studies on HCV risk factors were conducted
among high-risk groups such as sex workers, injecting
drug users and men who have sex with men and blood
transfusion [2, 6].
This study had several limitations, namely: The survey
was part of the antenatal sentinel sites sero-surveillance
and therefore findings are applied to pregnant women in
sentinel sites and cannot be generalized to the whole
population in Rwanda or to pregnant women in other
sub-Saharan African countries. Secondly, due to the small
number of HCV and HIV co-infected pregnant women in
our survey, it was not possible to assess the magnitude of
this co-infection in selected socio-demographic character-
istics sub-groups. Thirdly, in the present survey, Abbott
ARCHITECT system is a screening test with high sensitiv-
ity. Therefore, in the context of our study, this screening
test that was originally used in blood transfusion services
to minimize hepatitis C transmission from blood donors;
we may have some false HCVAb-positive results.
Conclusion
HCV-infection is a public health burden among pregnant
women in Rwanda. This study provides a platform to in-
form policymakers and stakeholders the need to accelerate
progress in treatment access and global prevention of
HCV infections.
Further advanced studies of HCV in this group and in
the general population are needed to explore detection
of Antigens and Antibodies and how they inform the
diagnosis of acute and active HCV infections.
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